Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Differential expression of fourteen proteins between uveal melanoma from patients who subsequently developed distant metastases versus those who did Not.

Linge A, Kennedy S, O'Flynn D, Beatty S, Moriarty P, Henry M, Clynes M, Larkin A, Meleady P.

Invest Ophthalmol Vis Sci. 2012 Jul 9;53(8):4634-43. doi: 10.1167/iovs.11-9019.

PMID:
22570344
2.

Proteomics of uveal melanomas suggests HSP-27 as a possible surrogate marker of chromosome 3 loss.

Coupland SE, Vorum H, Mandal N, Kalirai H, Honoré B, Urbak SF, Lake SL, Dopierala J, Damato B.

Invest Ophthalmol Vis Sci. 2010 Jan;51(1):12-20. doi: 10.1167/iovs.09-3913. Epub 2009 Jul 30.

PMID:
19643972
3.

Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target.

All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, Larsson O.

Invest Ophthalmol Vis Sci. 2002 Jan;43(1):1-8.

PMID:
11773005
4.

Expression of p53-induced apoptosis effector PERP in primary uveal melanomas: downregulation is associated with aggressive type.

Paraoan L, Gray D, Hiscott P, Ebrahimi B, Damato B, Grierson I.

Exp Eye Res. 2006 Oct;83(4):911-9. Epub 2006 Jun 19.

PMID:
16784742
5.

Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study.

Kadkol SS, Lin AY, Barak V, Kalickman I, Leach L, Valyi-Nagy K, Majumdar D, Setty S, Maniotis AJ, Folberg R, Pe'er J.

Invest Ophthalmol Vis Sci. 2006 Mar;47(3):802-6.

6.

Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers.

Khatib N, Pe'er J, Ortenberg R, Schachter J, Frenkel S, Markel G, Amer R.

Invest Ophthalmol Vis Sci. 2011 Dec 9;52(13):9368-72. doi: 10.1167/iovs.10-6006.

PMID:
22039239
7.

Proteomic analysis of uveal melanoma reveals novel potential markers involved in tumor progression.

Zuidervaart W, Hensbergen PJ, Wong MC, Deelder AM, Tensen CP, Jager MJ, Gruis NA.

Invest Ophthalmol Vis Sci. 2006 Mar;47(3):786-93.

PMID:
16505008
8.

An immunohistochemical analysis of nm23 gene product expression in uveal melanoma.

Greco IM, Calvisi G, Ventura L, Cerrito F.

Melanoma Res. 1997 Jun;7(3):231-6.

PMID:
9195562
9.

Melanoma inhibitory activity: a novel serum marker for uveal melanoma.

Schaller UC, Bosserhoff AK, Neubauer AS, Buettner R, Kampik A, Mueller AJ.

Melanoma Res. 2002 Dec;12(6):593-9.

PMID:
12459649
10.

Heat shock protein expression in the eye and in uveal melanoma.

Missotten GS, Journée-de Korver JG, de Wolff-Rouendaal D, Keunen JE, Schlingemann RO, Jager MJ.

Invest Ophthalmol Vis Sci. 2003 Jul;44(7):3059-65.

PMID:
12824252
11.

Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy.

López MN, Pereda C, Ramírez M, Mendoza-Naranjo A, Serrano A, Ferreira A, Poblete R, Kalergis AM, Kiessling R, Salazar-Onfray F.

Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1219-27.

PMID:
17325166
12.

Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression.

Gangemi R, Mirisola V, Barisione G, Fabbi M, Brizzolara A, Lanza F, Mosci C, Salvi S, Gualco M, Truini M, Angelini G, Boccardo S, Cilli M, Airoldi I, Queirolo P, Jager MJ, Daga A, Pfeffer U, Ferrini S.

PLoS One. 2012;7(1):e29989. doi: 10.1371/journal.pone.0029989. Epub 2012 Jan 13.

13.

Cripto-1 expression in uveal melanoma: an immunohistochemical study.

Mallikarjuna K, Vaijayanthi P, Krishnakumar S.

Exp Eye Res. 2007 Jun;84(6):1060-6. Epub 2007 Feb 7.

PMID:
17412323
14.

iTRAQ Quantitative Proteomic Comparison of Metastatic and Non-Metastatic Uveal Melanoma Tumors.

Crabb JW, Hu B, Crabb JS, Triozzi P, Saunthararajah Y, Tubbs R, Singh AD.

PLoS One. 2015 Aug 25;10(8):e0135543. doi: 10.1371/journal.pone.0135543. eCollection 2015.

15.

Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis.

Chang SH, Worley LA, Onken MD, Harbour JW.

Melanoma Res. 2008 Jun;18(3):191-200. doi: 10.1097/CMR.0b013e3283005270.

PMID:
18477893
16.

Proteomics in uveal melanoma.

Ramasamy P, Murphy CC, Clynes M, Horgan N, Moriarty P, Tiernan D, Beatty S, Kennedy S, Meleady P.

Exp Eye Res. 2014 Jan;118:1-12. doi: 10.1016/j.exer.2013.09.005. Epub 2013 Sep 19. Review.

PMID:
24056206
17.

c-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target?

All-Ericsson C, Girnita L, Müller-Brunotte A, Brodin B, Seregard S, Ostman A, Larsson O.

Invest Ophthalmol Vis Sci. 2004 Jul;45(7):2075-82.

PMID:
15223779
18.

EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation.

Neumann LC, Weinhäusel A, Thomas S, Horsthemke B, Lohmann DR, Zeschnigk M.

BMC Cancer. 2011 Aug 26;11:380. doi: 10.1186/1471-2407-11-380.

19.

Expression of CD133 and other putative stem cell markers in uveal melanoma.

Thill M, Berna MJ, Grierson R, Reinhart I, Voelkel T, Piechaczek C, Galambos P, Jager MJ, Richard G, Lange C, Gehling UM.

Melanoma Res. 2011 Oct;21(5):405-16. doi: 10.1097/CMR.0b013e328348db10.

PMID:
21900792
20.

Identification of differentially-expressed proteins between early submucosal non-invasive and invasive colorectal cancer using 2D-DIGE and mass spectrometry.

Zhang J, Song MQ, Zhu JS, Zhou Z, Xu ZP, Chen WX, Chen NW.

Int J Immunopathol Pharmacol. 2011 Oct-Dec;24(4):849-59.

PMID:
22230392
Items per page

Supplemental Content

Write to the Help Desk